title: Osteopontin and alphavbeta3 integrin as markers of endometrial receptivity: the effect of different hormone therapies.
abstract: The osteopontin: alphavbeta3 integrin complex has been proposed as a means of distinguishing receptive from non-receptive endometrium in clinical practice, thus offering new directions for the development of contraceptive approaches targeted to the endometrium as well as a better understanding of occult causes of infertility in women. Histological dating and immunohistochemical study were performed in control and study cycles in seven groups of women including 10 subjects per group and who received clomiphene citrate, ovarian stimulation for IVF, oral contraception, dehydrogesterone for endometrial luteal phase defect, two different regimens of hormone replacement therapy, or no treatment. Ten healthy fertile women served as a general control group. Osteopontin and alphavbeta3 integrin expression in the human endometrium was closely related to endometrial maturation and this was irrespective of the endometrium being in-phase or out-of-phase and the hormonal treatment (or no treatment) received. In conclusion, immunohistochemical assessment of the endometrium indicates that the use of osteopontin and alphavbeta3 integrin or the osteopontin: alphavbeta3 integrin complex as targets for the development of contraceptive approaches or the understanding of the pathogenesis of female infertility offer little benefit compared with simple histological dating.
authors.affiliation: Institut Clinic of Gynaecology, Obstetrics and Neonatology, Barcelona, Spain.
authors.forename: Gemma
authors.initials: G
authors.lastname: Casals
authors.forename: Jaume
authors.initials: J
authors.lastname: Ordi
authors.forename: Montserrat
authors.initials: M
authors.lastname: Creus
authors.forename: Francisco
authors.initials: F
authors.lastname: Fábregues
authors.forename: Francisco
authors.initials: F
authors.lastname: Carmona
authors.forename: Roser
authors.initials: R
authors.lastname: Casamitjana
authors.forename: Juan
authors.initials: J
authors.lastname: Balasch
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000378:metabolism; D002996:Clomiphene / Q000008:administration & dosage; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage; D004394:Dydrogesterone / Q000008:administration & dosage; D004717:Endometrium / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D015914:Estrogen Replacement Therapy; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D007150:Immunohistochemistry; D007247:Infertility, Female / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D053495:Osteopontin / Q000378:metabolism*; D055815:Young Adult
chemical_list: D015415:Biomarkers; D003277:Contraceptives, Oral, Combined; D039302:Integrin alphaVbeta3; D053495:Osteopontin; D002996:Clomiphene; D004394:Dydrogesterone